How to buy Mediwound stock (MDWD)

Mediwound is a biotechnology business based in the US. Mediwound shares (MDWD) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $17.70 – an increase of 7.34% over the previous week. Mediwound employs 100 staff and has a trailing 12-month revenue of around $20.1 million.

Our top picks for where to buy Mediwound stock

Buy Mediwound stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Mediwound stock price (NASDAQ: MDWD)

Use our graph to track the performance of MDWD stocks over time.

Mediwound shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$17.70
52-week range	$10.14 - $24.00
50-day moving average more info button	$17.29
200-day moving average more info button	$17.22
Wall St. target price	$29.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.91

Is it a good time to buy Mediwound stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Mediwound price performance over time

Historical closes compared with the close of $17.83 from 2024-12-26

1 week (2024-12-20)	8.13%
1 month (2024-11-27)	2.18%
3 months (2024-09-27)	1.48%
6 months (2024-06-28)	14.88%

1 year (2023-12-28)	73.61%
2 years (2022-12-28)	38.54%
3 years (2021-12-27)	7.02%
5 years (2019-12-27)	21.14

Mediwound financials

Revenue TTM	$20.1 million
Gross profit TTM	$13.2 million
Return on assets TTM	-15.77%
Return on equity TTM	-75.66%
Profit margin	-99.17%
Book value	$3.43
Market Capitalization more info button	$193 million

TTM: trailing 12 months

Mediwound share dividends

We're not expecting Mediwound to pay a dividend over the next 12 months.

Have Mediwound's shares ever split?

Mediwound's shares were split on a 1:7 basis on 19 December 2022 . So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Mediwound shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Mediwound shares which in turn could have impacted Mediwound's share price.

Mediwound share price volatility

Over the last 12 months, Mediwound's shares have ranged in value from as little as $10.1401 up to $24. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mediwound's is 0.838. This would suggest that Mediwound's shares are less volatile than average (for this exchange).

Mediwound overview

MediWound Ltd. , a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel. .

Frequently asked questions

What percentage of Mediwound is owned by insiders or institutions?
Currently 19.754% of Mediwound shares are held by insiders and 45.504% by institutions. How many people work for Mediwound?
Latest data suggests 100 work at Mediwound. When does the fiscal year end for Mediwound?
Mediwound's fiscal year ends in December. Where is Mediwound based?
Mediwound's address is: 42 Hayarkon Street, Yavne, Israel, 8122745 What is Mediwound's ISIN number?
Mediwound's international securities identification number is: IL0011316309 What is Mediwound's CUSIP number?
Mediwound's Committee on Uniform Securities Identification Procedures number is: M68830104